Toxicity testing by category for 30,000 chemicals?
SIR -Thomas Hartung and Costanza Rovinda in their Opinion article (Nature 460, 1080-1081; 2009) argue that the European Chemicals Agency has underestimated the impact of European Union (EU) legislation on animal testing by six times, and that some toxicity tests should be suspended. Unfortunately, pragmatic solutions for the implementation of reduced animal testing under the EU's REACH legislation -for registration, evaluation, authorization and restriction of chemicals -have not yet been formulated in a clear operational manner.
On the basis of the experience in the US High Production Volume Challenge Program, where nontesting approaches have been applied successfully, the goals for REACH can be formulated in a 'smart' manner. In this US programme, around 81% of the chemicals were included in a chemical category and new testing was proposed for fewer than 10% of the human-health and ecotoxicity end-point data needed (K. Van Leeuwen et al. SAR QSAR Environ. Res. 20, 207-220; 2009 Since then, more thematic, taxonomic and regional networks have been created. Each of these feeds into a growing biodiversityinformatics community, including the Global Biodiversity Information Facility, which serves users with up to 189 million plant and animal records. The vertebrate-based biodiversity networks -including MaNIS, HerpNET, ORNIS and FishNet 2 -serve some 4% of their combined holdings each day to users hungry for these data.
Sustaining these resources is difficult. Growth has led to problems with scalability and sustainability, including difficulties in keeping resources running, slow provider response times and complicated installations and maintenance. The National Biological Information Infrastructure has provided Authors beware, and protect your online identity SIR -Goudarz Molaei is right to express concern in his Correspondence about simultaneous submission of manuscripts to different journals (Nature 461, 723; 2009). As a professional journal editor with more than 20 years' experience, I would like to highlight here a worrying new problem I recently encountered: duplicate submission arising from author impersonation.
Unfortunately, online submission and review systems inadvertently encourage this unwelcome activity. For example, a co-author or colleague may be given the corresponding author's account password in order to submit his or her manuscripts -perhaps because of the corresponding author's lack of time or unfamiliarity with file creation and uploading. These people are then able to change the author's accounts, including the passwords, and submit manuscripts in that person's name without their knowledge.
So, authors, be wary of who has access to your account. Keep a check on what's happening and change your password after files have been submitted. support, and the vertebrate networks are consolidating into a platform called VertNet. In order to reduce IT costs, VertNet will move from institutional servers to a cloud computing platform, providing nearly unlimited room for growth.
But solving technological challenges is not enough. Our success has depended on strong engagement with our contributor and user community. Capacity building in biodiversity informatics is especially important. Success requires willing participation, robust technology choices and a commitment to engage fully with the communities these repositories will serve. Contributions may be sent to correspondence@nature.com and will be edited before publication. Please see the Guide to Authors at go.nature.com/cMCHno.
Robert Guralnick

Eastern European science stuck in an outmoded system
SIR -The problem that Jan Konvalinka and colleagues identify in their Correspondence -that the Czech bibliometric system for assessing grant proposals encourages mediocre research (Nature 460, 1079; 2009) -is widespread in eastern Europe. Some policymakers are upholding the old systems for allocating funds in public universities and research institutes, rather than using them to promote the best science.
In Slovenia, a bibliometric system introduced a few years ago provides the main criteria for awarding research grants by national government, often overriding peer-reviewed evaluation. It divides scientific journals into categories that disregard impact factors, on the grounds that journals vary in quality for different fields. Although there may be some justification for the thinking behind this, the system in practice favours researchers who publish in low-impact journals over those who are struggling to do internationally competitive science and to publish in the best journals.
For example, a Slovenian endocrinologist might choose to publish a basic animal study in a prestigious endocrinology journal or in a much lower-impact agricultural journal. If the latter journal is rated at a higher position among agricultural journals than the former is in the field of endocrinology, the researcher will receive more points for publishing in the low-impact agricultural journal.
Likewise, a review article in a journal with no impact factor (but included in SCI, the science citation index) could be worth as many as 20 Slovenian bibliometric points, whereas one paper that was recently published in Nature -the result of years of work -gained its authors just 18.75 points each.
With the exception of the former East Germany, many universities and science policies First, the quality-of-life evaluation mentioned in your News Feature (Nature 461, 336-339; 2009) needs more thought. NICE would achieve more if it valued health interventions according to the real suffering of patients, rather than on the basis of the hypothetical preferences of the public. There is evidence showing that the public are often prepared to sacrifice more life years than patients might be.
Also, public and patient preferences can misrepresent the impact of a particular state of health on our experiences (P. Dolan and D. Kahneman Econ. J. 118, 215-234; 2008) . For example, we may imagine physical pain to be more severe than depression, but depression can make us feel worse and so we evaluate our lives less favourably.
Second, NICE should not raise the cost per quality-adjusted life year (QALY) threshold for some conditions, such as the end of life, until there is good evidence for doing so. The threshold varies across different conditions. From an implicit default position where all QALYs are treated equally, NICE can now give greater weight to QALYs at the later stages of a terminal disease. NICE justifies this position as being in accordance with the views of the general public -yet the evidence in this regard is actually quite weak.
There is some support from NICE's Citizens' Council for spending more on end-of-life care, but this preference has not been elicited in the context of what people would give up for it. In a choice between prioritizing end of life and reducing inequalities in lifetime health, it is likely that the general public would choose the latter (see go.nature.com/ QgnrFX). 
Paul Dolan
